The Urology Group | Cincinnati, OH
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
678 participants in 1 patient group
Loading...
Central trial contact
Bayer Clinical Trials Contact
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal